Table 2.
CD20 positive. n-48 patients | CD20negative .n-6 patients | |
---|---|---|
Mean age | 55.3 | 53.6 |
Gender | ||
Males | 29(60%) | 5(83.3%) |
Females | 19(40%) | 1(16.6) |
RIPI | II/III | II/III |
Initial regimen | ||
R-CHOP | 39(69.6%) | 5(83.3%) |
RCVP | 7(13%) | 1(16.7%) |
REPOCH | 2(3.7%) | |
Response to First line treatment | ||
CR | 26(48%) | 2(33%) |
Relapsed | 24(50%) | 2(33%) |
Refractory | 24(50%) | 4(66.6%) |
Salvage chemo | ||
RDHAP/DHAP | 8(33.3%) | 3(50%) |
ICE | 5(21%) | 1(16.6%) |
Others | 4(16.6%) | 2(33.3%) |
Site of relapse | ||
Lymph nodes | 11(46%) | 0 |
GIT | 4(14.6%) | 2(100%) |
Response to salvage Chemo | ||
Complete response | 12(50%) | 2(33%) |
Refractory | 28(44.4%) | 4(14.3%) |
Median DFS(Months) | 12 | 9 |
Median OS (Months) | 17.5 | 13 |